Fort L.P. increased its holdings in Celgene Co. (NASDAQ:CELG) by 24.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 33,987 shares of the biopharmaceutical company’s stock after buying an additional 6,575 shares during the period. Celgene comprises approximately 0.5% of Fort L.P.’s holdings, making the stock its 23rd biggest position. Fort L.P.’s holdings in Celgene were worth $2,178,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Bessemer Group Inc. grew its holdings in Celgene by 8.0% during the third quarter. Bessemer Group Inc. now owns 16,341 shares of the biopharmaceutical company’s stock valued at $1,463,000 after purchasing an additional 1,211 shares during the period. LSV Asset Management grew its holdings in Celgene by 55.3% during the third quarter. LSV Asset Management now owns 87,037 shares of the biopharmaceutical company’s stock valued at $7,788,000 after purchasing an additional 31,000 shares during the period. Toronto Dominion Bank grew its holdings in Celgene by 2.6% during the third quarter. Toronto Dominion Bank now owns 473,365 shares of the biopharmaceutical company’s stock valued at $42,352,000 after purchasing an additional 11,863 shares during the period. Edgestream Partners L.P. bought a new stake in Celgene during the third quarter valued at about $315,000. Finally, Commonwealth Bank of Australia grew its holdings in Celgene by 2.0% during the third quarter. Commonwealth Bank of Australia now owns 45,301 shares of the biopharmaceutical company’s stock valued at $4,048,000 after purchasing an additional 900 shares during the period. 74.19% of the stock is owned by institutional investors and hedge funds.
NASDAQ CELG opened at $88.29 on Friday. The company has a debt-to-equity ratio of 3.21, a current ratio of 2.23 and a quick ratio of 2.12. The stock has a market capitalization of $60.12 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 0.39 and a beta of 1.69. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $95.30.
Several research firms have issued reports on CELG. Cantor Fitzgerald reissued a “buy” rating and set a $100.00 price target on shares of Celgene in a report on Thursday, January 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 5th. Goldman Sachs Group raised Celgene from a “sell” rating to a “neutral” rating and boosted their price target for the company from $71.00 to $88.00 in a report on Thursday, January 3rd. Jefferies Financial Group lowered Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Friday, February 1st. Finally, reissued a “buy” rating on shares of Celgene in a report on Monday, December 3rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene has a consensus rating of “Hold” and a consensus price target of $100.94.
In related news, Director James J. Loughlin sold 23,466 shares of the business’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the sale, the director now directly owns 62,102 shares in the company, valued at $5,420,883.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ernest Mario bought 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was purchased at an average price of $89.99 per share, for a total transaction of $179,980.00. The disclosure for this purchase can be found here. 0.39% of the stock is currently owned by insiders.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Google Finance
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.